Skip to main content
Top
Literature
1.
go back to reference Sakai T, Kato N, Kubota M, Tsuneoka H (2017) Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 255(8):1565–1571CrossRefPubMed Sakai T, Kato N, Kubota M, Tsuneoka H (2017) Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 255(8):1565–1571CrossRefPubMed
2.
go back to reference Kawamura A, Yuzawa M, Mori R, Haruyama M, Tanaka K (2013) Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types. Acta Ophthalmol 91(6):e474–e481CrossRefPubMed Kawamura A, Yuzawa M, Mori R, Haruyama M, Tanaka K (2013) Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types. Acta Ophthalmol 91(6):e474–e481CrossRefPubMed
3.
go back to reference Jeong S, Sagong M (2017) Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy. Br J Ophthalmol 101(6):758–763CrossRefPubMed Jeong S, Sagong M (2017) Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy. Br J Ophthalmol 101(6):758–763CrossRefPubMed
4.
go back to reference Călugăru D, Călugăru M (2017) Comparison of time to retreatment and visual function between ranibizumab and aflibercept in age-related macular degeneration. Am J Ophthalmol 174(2):181–182PubMed Călugăru D, Călugăru M (2017) Comparison of time to retreatment and visual function between ranibizumab and aflibercept in age-related macular degeneration. Am J Ophthalmol 174(2):181–182PubMed
5.
go back to reference Călugăru D, Călugăru M (2017) Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization. Eur J Ophthalmol 27(3):107–108 Călugăru D, Călugăru M (2017) Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization. Eur J Ophthalmol 27(3):107–108
6.
go back to reference Călugăru D, Călugăru M (2017) Intravitreal dexamethasone implant as adjuvant treatment for bevacizumab- and ranibizumab-resistant neovascular age-related macular degeneration. Retina 37(6):78–79CrossRef Călugăru D, Călugăru M (2017) Intravitreal dexamethasone implant as adjuvant treatment for bevacizumab- and ranibizumab-resistant neovascular age-related macular degeneration. Retina 37(6):78–79CrossRef
7.
go back to reference Călugăru D, Călugăru M (2017) Long-term results of pro re nata regimen of aflibercept treatment in persistent neovacular age-related macular degeneration. Am J Ophthalmol 173(1):145–146PubMed Călugăru D, Călugăru M (2017) Long-term results of pro re nata regimen of aflibercept treatment in persistent neovacular age-related macular degeneration. Am J Ophthalmol 173(1):145–146PubMed
8.
go back to reference Mukai R, Kishi S, Sato T, Watanabe G, Matsumoto H (2010) Protective effect of intravitreal bevacizumab and sub-tenon triamcinolone acetonide against occlusion of choriocapillaris induced by photodynamic therapy. Ophthalmoloica 224(5):267–273CrossRef Mukai R, Kishi S, Sato T, Watanabe G, Matsumoto H (2010) Protective effect of intravitreal bevacizumab and sub-tenon triamcinolone acetonide against occlusion of choriocapillaris induced by photodynamic therapy. Ophthalmoloica 224(5):267–273CrossRef
9.
go back to reference Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31(6):357–362CrossRefPubMed Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31(6):357–362CrossRefPubMed
10.
go back to reference Julien S, Biesemeier A, Taubitz T, Schraemeyer U (2014) Different effects on intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues on monkey eyes. Br J Ophthalmol 98(6):813–825CrossRefPubMed Julien S, Biesemeier A, Taubitz T, Schraemeyer U (2014) Different effects on intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues on monkey eyes. Br J Ophthalmol 98(6):813–825CrossRefPubMed
Metadata
Title
Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy
Authors
Dan Călugăru
Mihai Călugăru
Publication date
01-01-2018
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 1/2018
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-017-3797-4

Other articles of this Issue 1/2018

Graefe's Archive for Clinical and Experimental Ophthalmology 1/2018 Go to the issue